Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and...

Drug delivery company Taiwan Liposome Co. Ltd. (TPEx:4152) proposed to raise up to $50 million on Feb. 17 through the sale of ADSs in a NASDAQ listing underwritten by Cantor Fitzgerald, CLSA, H.C. Wainwright, Janney...

Taiwan Liposome Co. Ltd. (TPEx:4152) proposed to raise up to $50 million through the sale of ADSs in a NASDAQ listing underwritten by Cantor Fitzgerald, CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw. The company...

Taiwan Liposome Co. Ltd. (TPEx:4152) said it entered into a joint venture with Jixi Biotechnology to promote and market Taiwan Liposome's drugs more efficiently in China. Jixi will invest $20 million to purchase a partial...

Taiwan Liposome Co. Ltd. (TPEx:4152) said it entered into a joint venture with Jixi Biotechnology to promote and market its drugs more efficiently in China. Jixi will invest $20 million to purchase a partial stake...

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported data from three evaluable patients with chronic refractory mucocutaneous candidiasis in a Phase IIa trial showing that oral MAT2203 (CAmB) met the primary endpoint of reducing clinical symptoms. To...

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....

University of York scientists have shown skin, not just blood, is a major route by which Leishmania parasites spread from visceral leishmaniasis (VL) patients to the sand fly vector and back to a new host....

The identification of ERK-5 as a brake on the process of macrophage vomocytosis not only provides new mechanistic insight into the poorly understood phenomenon but could lead to a strategy for preventing dissemination of fungal...

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported top-line data from a Phase II trial to treat moderate to severe vulvovaginal candidiasis showing that oral CAmB (MAT2203) met the primary safety endpoint but missed the secondary efficacy...